IPM Take
The next pancreatic-cancer breakthrough may not come from a single miracle drug. It may come from building a system that can measure the right antigen, at the right time, in the right patient, and then deliver the treatment without losing weeks to referral and testing delays.
Executive Summary
At ESMO GI, investigators reported early results for precemtabart tocentecan, also known as Precem-TcT, an anti-CEACAM5 antibody–drug conjugate, in refractory pancreatic ductal adenocarcinoma with high CEACAM5 expression. In the Phase Ib/II PROCEADE PanTumor study, 46 patients were treated in the pancreatic-cancer cohort. In the second-line group, confirmed objective response rate was 24.0% and median progression-free survival was 5.3 months after a median follow-up of 6.8 months. Treatment-related adverse events led to permanent discontinuation in 13% of patients; no interstitial lung disease or treatment-related deaths were reported.
Why it matters
- Patients / advocates: Pancreatic cancer has too few effective options after first-line treatment, but early signals must not be overstated.
- Clinicians: The data add a potential new treatment class in a difficult setting, while reinforcing the need for careful toxicity monitoring.
- Diagnostics / pathology: CEACAM5 expression is doing more than decorating a pathology report; it is becoming part of a possible treatment-selection pathway.
- Health systems: ADC delivery will require testing capacity, molecular interpretation, infusion infrastructure and clear toxicity-management protocols.
The phrase “ADC revolution” has become fashionable in oncology.
Pancreatic cancer does not care about fashionable.
It cares about whether an experimental treatment can produce enough benefit, in the right patients, to justify another infusion, another side-effect profile and another difficult decision after standard therapy has failed.
The early data for precemtabart tocentecan deserve attention because they point to a possible new route in a disease that has resisted too many of them. The anti-CEACAM5 antibody–drug conjugate was tested in patients with second- or third-line pancreatic ductal adenocarcinoma whose tumours showed high CEACAM5 expression. In the second-line cohort, the confirmed response rate was 24%, and median progression-free survival was 5.3 months.
This is not a practice-changing result. Not yet.
The cohort is small, the study is early phase, and selection matters enormously. The patients were not simply diagnosed with pancreatic cancer; they were selected for high CEACAM5 expression. That detail is the whole story. An ADC can only become a real personalised-medicine tool when the biomarker behind it is measured consistently, interpreted properly and linked to a pathway that patients can use before they run out of time.
The safety signal also needs to stay visible. Permanent discontinuation because of adverse events occurred in 13% of treated patients. There were no reported cases of interstitial lung disease and no treatment-related deaths in this cohort, which is reassuring, but it does not erase the practical burden of ADC treatment in a population already carrying a heavy disease load.
The policy question is straightforward. Does Europe want biomarker-driven pancreatic care to remain a research-centre privilege, or does it want testing, referral and treatment capability to develop as one integrated pathway?
The medicine may be new. The implementation problem is very old.
